01801 PE Ratio & Valuation,Is 01801 Overvalued

01801 Relative Valuation

01801's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, 01801 is overvalued; if below, it's undervalued.

Historical Valuation

INNOVENT BIO (01801) is now in the Fair zone, suggesting that its current forward PS ratio of 8.00 is considered Fairly compared with the five-year average of 77.31. The fair price of INNOVENT BIO (01801) is between 40.85 to 136.86 according to relative valuation methord.

Relative Value

Fair Zone

40.85-136.86

Current Price：89.00

Fair

50.91

63.34

EV/EBITDA

INNOVENT BIO. (01801) has a current EV/EBITDA of 63.34. The 5-year average EV/EBITDA is -40.98. The thresholds are as follows: Strongly Undervalued below -374.21, Undervalued between -374.21 and -207.59, Fairly Valued between 125.63 and -207.59, Overvalued between 125.63 and 292.24, and Strongly Overvalued above 292.24. The current Forward EV/EBITDA of 63.34 falls within the Historic Trend Line -Fairly Valued range.

51.57

EV/EBIT

INNOVENT BIO. (01801) has a current EV/EBIT of 51.57. The 5-year average EV/EBIT is -7.59. The thresholds are as follows: Strongly Undervalued below -265.30, Undervalued between -265.30 and -136.45, Fairly Valued between 121.27 and -136.45, Overvalued between 121.27 and 250.13, and Strongly Overvalued above 250.13. The current Forward EV/EBIT of 51.57 falls within the Historic Trend Line -Fairly Valued range.

8.00

INNOVENT BIO. (01801) has a current PS of 8.00. The 5-year average PS is 9.99. The thresholds are as follows: Strongly Undervalued below -0.82, Undervalued between -0.82 and 4.59, Fairly Valued between 15.40 and 4.59, Overvalued between 15.40 and 20.80, and Strongly Overvalued above 20.80. The current Forward PS of 8.00 falls within the Historic Trend Line -Fairly Valued range.

37.93

P/OCF

INNOVENT BIO. (01801) has a current P/OCF of 37.93. The 5-year average P/OCF is -44.28. The thresholds are as follows: Strongly Undervalued below -405.06, Undervalued between -405.06 and -224.67, Fairly Valued between 136.10 and -224.67, Overvalued between 136.10 and 316.49, and Strongly Overvalued above 316.49. The current Forward P/OCF of 37.93 falls within the Historic Trend Line -Fairly Valued range.

75.59

P/FCF

INNOVENT BIO. (01801) has a current P/FCF of 75.59. The 5-year average P/FCF is 1504.45. The thresholds are as follows: Strongly Undervalued below -7338.99, Undervalued between -7338.99 and -2917.27, Fairly Valued between 5926.16 and -2917.27, Overvalued between 5926.16 and 10347.88, and Strongly Overvalued above 10347.88. The current Forward P/FCF of 75.59 falls within the Historic Trend Line -Fairly Valued range.

INNOVENT BIO (01801) has a current Price-to-Book (P/B) ratio of 8.60. Compared to its 3-year average P/B ratio of 5.77 , the current P/B ratio is approximately 49.05% higher. Relative to its 5-year average P/B ratio of 5.99, the current P/B ratio is about 43.58% higher. INNOVENT BIO (01801) has a Forward Free Cash Flow (FCF) yield of approximately 1.19%. Compared to its 3-year average FCF yield of -1.79%, the current FCF yield is approximately -166.29% lower. Relative to its 5-year average FCF yield of -3.01% , the current FCF yield is about -139.57% lower.

8.60

P/B

Median3y

5.77

Median5y

5.99

1.19

FCF Yield

Median3y

-1.79

Median5y

-3.01

Performance Decomposition

Market capitalization of 01801 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of 01801 in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is INNOVENT BIO (01801) currently overvalued or undervalued?

What is INNOVENT BIO (01801) fair value?

01801's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of INNOVENT BIO (01801) is between 40.85 to 136.86 according to relative valuation methord.

How does 01801's valuation metrics compare to the industry average?

The average P/S ratio for 01801's competitors is , providing a benchmark for relative valuation. INNOVENT BIO Corp (01801) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for INNOVENT BIO (01801) as of Jan 08 2026?

As of Jan 08 2026, INNOVENT BIO (01801) has a P/B ratio of 8.60. This indicates that the market values 01801 at 8.60 times its book value.

What is the current FCF Yield for INNOVENT BIO (01801) as of Jan 08 2026?

As of Jan 08 2026, INNOVENT BIO (01801) has a FCF Yield of 1.19%. This means that for every dollar of INNOVENT BIO’s market capitalization, the company generates 1.19 cents in free cash flow.

What is the current Forward P/E ratio for INNOVENT BIO (01801) as of Jan 08 2026?

As of Jan 08 2026, INNOVENT BIO (01801) has a Forward P/E ratio of 50.91. This means the market is willing to pay $50.91 for every dollar of INNOVENT BIO’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for INNOVENT BIO (01801) as of Jan 08 2026?

As of Jan 08 2026, INNOVENT BIO (01801) has a Forward P/S ratio of 8.00. This means the market is valuing 01801 at $8.00 for every dollar of expected revenue over the next 12 months.

01801 Valuation